Trabectedin for the management of soft-tissue sarcoma

References

• Rinehart KL. Antitumor compounds from tunicates. Med. Res. Rev.20(1), 1–27 (2000).
   PubMed Web of Science ®Google Scholar
• Cuevas C, Perez M, Martin MJ et al. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Org. Lett.2(16), 2545–2548 (2000).
   PubMed Web of Science ®Google Scholar
• David-Cordonnier MH, Gajate C, Olmea O et al. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem. Biol.12(11), 1201–1210 (2005).
   PubMed Web of Science ®Google Scholar
• Takebayashi Y, Pourquier P, Zimonjic DB et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med.7(8), 961–966 (2001).
   PubMed Web of Science ®Google Scholar
• Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res.62(12), 3377–3381 (2002).
   PubMed Web of Science ®Google Scholar
• Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res.66(16), 8155–8162 (2006).
   PubMed Web of Science ®Google Scholar
• Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin. Cancer Res.7(1), 185–191 (2001).
   PubMed Web of Science ®Google Scholar
• Soares DG, Escargueil AE, Poindessous V et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc. Natl Acad. Sci. USA104(32), 13062–13067 (2007).
   PubMed Web of Science ®Google Scholar
• Guirouilh-Barbat J, Redon C, Pommier Y. Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11–Rad50–Nbs1 complex. Mol. Biol. Cell19(9), 3969–3981 (2008).
   PubMed Web of Science ®Google Scholar
• Taamma A, Misset JL, Riofrio M et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J. Clin. Oncol.19(5), 1256–1265 (2001).
   PubMed Web of Science ®Google Scholar
• Ryan DP, Supko JG, Eder JP et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin. Cancer Res.7(2), 231–242 (2001).
   PubMed Web of Science ®Google Scholar
• Twelves C, Hoekman K, Bowman A et al. Phase I and pharmacokinetic study of Yondelis (ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur. J. Cancer39(13), 1842–1851 (2003).
   PubMed Web of Science ®Google Scholar
• Reid JM, Kuffel MJ, Ruben SL et al. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin. Cancer Res.8(9), 2952–2962 (2002).
   PubMed Web of Science ®Google Scholar
• Sparidans RW, Rosing H, Hillebrand MJ et al. Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man. Anticancer Drugs12(8), 653–666 (2001).
   PubMed Web of Science ®Google Scholar
• Brandon EF, Sparidans RW, Guijt KJ et al.In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, trabectidin), a novel marine anti-cancer drug. Invest. New Drugs24(1), 3–14 (2006).
   PubMed Web of Science ®Google Scholar
• Beumer JH, Buckle T, Ouwehand M et al. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Invest. New Drugs25(1), 1–7 (2007).
   PubMedGoogle Scholar
• Delaloge S, Yovine A, Taamma A et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients: preliminary evidence of activity. J. Clin. Oncol.19(5), 1248–1255 (2001).
   PubMed Web of Science ®Google Scholar
• Yovine A, Riofrio M, Blay JY et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J. Clin. Oncol.22(5), 890–899 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG, Manola J et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J. Clin. Oncol.22(8), 1480–1490 (2004).
   PubMed Web of Science ®Google Scholar
• LeCesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol.23(3), 576–584 (2005).
   PubMedGoogle Scholar
• Blay JY, Le CA, Verweij J et al. A Phase II study of ET-743/trabectedin (‘Yondelis’) for patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer40(9), 1327–1331 (2004).
   PubMedGoogle Scholar
• Ryan DP, Puchalski T, Supko JG et al. A Phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist7(6), 531–538 (2002).
   PubMed Web of Science ®Google Scholar
• Huygh G, Clement PM, Dumez H et al. Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma 56282 (2006).
   PubMedGoogle Scholar
• Garcia-Carbonero R, Supko JG, Maki RG et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter Phase II and pharmacokinetic study. J. Clin. Oncol.23(24), 5484–5492 (2005).
   PubMed Web of Science ®Google Scholar
• Samuels BL, Rushing D, Chawla SP et al. Randomized Phase II study of trabectedin (ET-743) given by two different dosing schedules in patients with leiomyosarcoma or liposarcomas refractory to conventional doxorubicin and ifosfamide chemotherapy. ASCO Meeting Abstracts22(14 Suppl.), 9000 (2004).
   Google Scholar
• Morgan JA, Le Cesne A, Chawla S et al. Randomized Phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (l-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I). ASCO Meeting Abstracts25(18 Suppl.), 10060 (2007).
   Google Scholar
• Grosso F, Demetri GD, Blay JY et al. Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas. ASCO Meeting Abstracts24(18 Suppl.), 9511 (2006).
   Google Scholar
• Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol.8(7), 595–602 (2007).
   PubMed Web of Science ®Google Scholar
• Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature363(6430), 640–644 (1993).
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Tschernyavsky SJ, Decuseara R et al. Prognostic impact of P53 status, TLS–CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin. Cancer Res.7(12), 3977–3987 (2001).
   PubMed Web of Science ®Google Scholar
• Grosso F, Forni C, Frapolli R et al. Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript. ASCO Meeting Abstracts25(18 Suppl.), 10000 (2007).
   Google Scholar
• Forni C, Minuzzo M, Virdis E et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol. Cancer Ther.8(2), 449–457 (2009).
   PubMed Web of Science ®Google Scholar
• Patel SR, Burgess MA, Plager C, Papadopoulos NE, Linke KA, Benjamin RS. Myxoid liposarcoma. Experience with chemotherapy. Cancer74(4), 1265–1269 (1994).
   PubMed Web of Science ®Google Scholar
• Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur. J. Cancer.41(18), 2853–2860 (2005).
   PubMed Web of Science ®Google Scholar
• Pitson G, Robinson P, Wilke D et al. Radiation response: an additional unique signature of myxoid liposarcoma. Int. J. Radiat. Oncol. Biol. Phys.60(2), 522–526 (2004).
   PubMed Web of Science ®Google Scholar
• Schoffski P, Casali PG, Taron M et al. DNA repair functionality modulates the clinical outcome of patients. ASCO Meeting Abstracts24(18 Suppl.), 9522 (2006).
   Google Scholar
• Villalona-Calero MA, Eckhardt SG, Weiss G et al. A Phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies. Clin. Cancer Res.8(1), 75–85 (2002).
   PubMed Web of Science ®Google Scholar
• Gomez J, Lopez-Lazaro L, Guzman C et al. Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. ASCO Meeting Abstracts19, 727 (2000).
   Google Scholar
• Donald S, Verschoyle RD, Greaves P et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res.63(18), 5902–5908 (2003).
   PubMed Web of Science ®Google Scholar
• Grosso F, Dileo P, Sanfilippo R et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur. J. Cancer42(10), 1484–1490 (2006).
   PubMed Web of Science ®Google Scholar
• McCune JS, Hawke RL, LeCluyse EL et al.In vivo and In vitro induction of human cytochrome P4503A4 by dexamethasone. Clin. Pharmacol. Ther.68(4), 356–366 (2000).
   PubMed Web of Science ®Google Scholar
• Lee JK, Leslie EM, Zamek-Gliszczynski MJ, Brouwer KL. Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity. Toxicol. Appl. Pharmacol.228(1), 17–23 (2008).
   PubMed Web of Science ®Google Scholar
• Salazar R, Pardo B, Majem M et al. Phase I clinical and pharmacological trial of trabectedin (T) in 3 hour infusion every 3 weeks (3h/q3w) in patients with advanced cancer and hepatic function disorder. ASCO Meeting Abstracts24(18 Suppl.), 2080 (2006).
   Google Scholar
• Messersmith WA, Jimeno A, Ettinger D et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother. Pharmacol.63(1), 181–188 (2008).
   PubMed Web of Science ®Google Scholar
• Von Mehren M, Schilder RJ, Cheng JD et al. A Phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann. Oncol.19(10), 1802–1809 (2008).
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog T, Kaye S et al. A randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian carcinoma (OC). Ann Oncol.19(Suppl. 8), LBA4 (2009).
   Google Scholar
• Blay JY, Von Mehren M, Samuels BL et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin. Cancer Res.14(20), 6656–6662 (2008).
   PubMed Web of Science ®Google Scholar
• Sessa C, Perotti A, Noberasco C et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur. J. Cancer.45(7), 1153–1161 (2009).
   PubMed Web of Science ®Google Scholar
• Von Mehren M, Buck D, Temmer E, Elsayed YA, Cohen RB. Phase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignancies. ASCO Meeting Abstracts24(18 Suppl.), 2068 (2006).
   Google Scholar
• Gore L, Rivera E, Lavallee K et al. Phase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignancies. ASCO Meeting Abstracts24(18 Suppl.), 2079 (2006).
   Google Scholar
• Grosso F, Demetri GD, Blay JY et al. Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas. ASCO Meeting Abstracts24(18 Suppl.), 9511 (2006).
   Google Scholar
• Schoffski P, Casali PG, Taron M et al. DNA repair functionality modulates the clinical outcome of patients. ASCO Meeting Abstracts24(18 Suppl.), 9522 (2006).
   Google Scholar
• Bay JO, Ray-Coquard I, Fayette J et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int. J. Cancer119(3), 706–711 (2006).
   PubMed Web of Science ®Google Scholar
• Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol.20(12), 2824–2831 (2002).
   PubMed Web of Science ®Google Scholar
• Maki RG, Keohan ML, Undevia SD et al. Updated results of a Phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060. ASCO Meeting Abstracts26(15 Suppl.), 10531 (2008).
   Google Scholar
• Ryan CW, Von Mehren M, Rankin CJ et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. ASCO Meeting Abstracts26(15 Suppl.), 10532 (2008).
   Google Scholar
• Sleijfer S, Papai Z, Le Cesne A et al. Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043. ASCO Meeting Abstracts25(18 Suppl.), 10031 (2007).
   Google Scholar
• Grosso F, Sanfilippo RG, Dileo P et al. Long-term benefit from trabectedin (T) in myxoid liposarcoma (MLS) patients. ASCO Meeting Abstracts26(15 Suppl.), 10582 (2008).
   Google Scholar
• Schoffski P, Casali PG, Taron M et al. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). ASCO Meeting Abstracts24(18 Suppl.), 9522 (2006).
   Google Scholar